If you have gout, you may wonder whether Wegovy (semaglutide), a GLP-1 medication, could make it worse. The most accurate answer is: possibly for some people during early, substantial weight loss, but the evidence is limited and does not prove cause and effect.
Gout is not listed as a warning or common adverse reaction in the current FDA prescribing information for Wegovy (semaglutide). A small report published in 2026 has raised a signal worth discussing, especially if you already have gout or high uric acid. It is not evidence that everyone taking a GLP-1 will develop gout.
What Gout Is
Gout is an inflammatory arthritis caused by monosodium urate crystals in and around joints. These crystals can form when serum urate remains high. A flare often causes sudden, intense pain, swelling, warmth, and redness, commonly in the big toe, foot, or ankle.
Body weight, kidney function, genetics, medications, alcohol, and diet can all affect urate or gout risk. That makes it difficult to attribute a flare during weight loss to one medication alone.
What the GLP-1 and Gout Evidence Actually Shows
A 2026 case series described only four people who lost substantial weight while taking semaglutide, a GLP-1 medication, or tirzepatide, a dual GIP/GLP-1 medication. Three had a rise in uric acid within three to five months, and two experienced gout flares.
Those observations are important, but they have major limitations:
- Four cases cannot show how common the problem is.
- Most participants already had gout or high uric acid.
- Other factors and medication changes could have contributed.
- Ketones were not measured, so the proposed ketosis mechanism was not proven.
- A case series can identify a possible signal, but it cannot establish that the medication or the pace of weight loss caused the events.
The longer-term picture may be different. In a post hoc analysis of the randomized SURMOUNT-1 trial, tirzepatide was associated with lower serum uric acid after 72 weeks, and much of that change was statistically linked to weight reduction. However, the analysis did not establish that tirzepatide prevents or treats gout flares.
Research on weight loss and gout is also mixed. The American College of Rheumatology (ACR) guideline conditionally recommends a weight-loss program for people with gout who have overweight or obesity, while rating the supporting evidence as very low certainty. Early urate changes during rapid nonsurgical weight loss remain insufficiently studied.
Bottom line: there may be an early flare or uric-acid signal in some at-risk people, while sustained weight loss may lower uric acid over time. Better prospective studies are needed.
If You Have Gout Before Starting a GLP-1
Tell the clinician prescribing your GLP-1 medication about:
- Previous gout flares, even if they were years ago
- Known high uric acid or kidney disease
- Kidney stones
- Allopurinol, febuxostat, colchicine, diuretics, or other relevant medicines
- Recent vomiting, diarrhea, or difficulty keeping fluids down
Do not stop allopurinol, febuxostat, or another urate-lowering medicine on your own. The ACR guideline conditionally recommends continuing urate-lowering therapy indefinitely rather than stopping it. Your clinician can decide whether symptoms, flare history, or serum urate testing call for a change.
There is no established weekly weight-loss cutoff at which a gout flare becomes likely, and there is no gout-specific rule that a GLP-1 dose must be reduced because weight is changing quickly. If you are losing weight faster than expected, cannot eat or drink normally, or have persistent gastrointestinal symptoms, contact your prescriber rather than changing the dose yourself.
Hydration and Food: Keep the Advice Proportionate
No authoritative gout guideline sets a universal target such as 80 ounces of water per day. Fluid needs vary, and some people with heart or kidney conditions may need individualized limits. Drink enough to avoid dehydration, and seek medical advice if nausea, vomiting, or diarrhea makes that difficult. The FDA semaglutide label warns that gastrointestinal reactions leading to dehydration can contribute to acute kidney injury.
For people with gout, the ACR conditionally recommends limiting alcohol, purine-heavy foods, and high-fructose corn syrup. These are supportive steps, not substitutes for prescribed gout treatment. The guideline also notes that dietary changes usually produce only small changes in serum urate.
Practical choices may include:
- Limiting beer, liquor, and other alcohol if it triggers flares
- Eating smaller portions of organ meats, red meat, and high-purine seafood
- Limiting drinks and foods high in high-fructose corn syrup
- Choosing an eating pattern you can maintain while meeting your nutrition needs
Vitamin C supplements are not a recommended gout-prevention strategy. The ACR conditionally recommends against adding vitamin C supplementation for people with gout.
What to Do During a Suspected Flare
Contact a healthcare professional for a first suspected flare or if the diagnosis is uncertain. A painful, red, swollen joint can have other causes, including infection, and may need prompt evaluation.
For a diagnosed gout flare, the ACR guideline recommends colchicine, a nonsteroidal anti-inflammatory drug (NSAID), or a glucocorticoid as first-line treatment. The right option depends on kidney function, other medical conditions, medication interactions, and individual risk. Use only the treatment and dose recommended for you; NSAIDs and colchicine are not safe for everyone.
Supportive steps can include:
- Resting the affected joint
- Using a wrapped cold pack as an add-on for pain, if comfortable
- Following your clinician's existing flare plan
- Avoiding self-directed changes to either your gout medicine or GLP-1 medicine
Seek urgent care if you have fever, feel seriously unwell, cannot keep fluids down, or have a hot and swollen joint without a confirmed gout diagnosis. Contact your clinician if a treated flare is not improving or keeps returning.
Questions to Ask Your Clinician
- Does my gout history change how you want to monitor me after I start treatment?
- Should my serum urate be checked based on my symptoms and history?
- What is my written plan if a flare starts?
- Which flare medicine is safest with my kidney function and other prescriptions?
- What should I do if vomiting or diarrhea makes hydration difficult?
The Bottom Line
Current evidence does not justify calling gout an established side effect of GLP-1 medications. A four-person case series suggests that uric acid may rise or gout may flare during early, substantial weight loss in some people, particularly those already at risk. Other research suggests uric acid can fall with longer-term weight reduction.
If you have gout, discuss it before starting semaglutide, a GLP-1 medication, or another incretin-based treatment. Keep taking prescribed gout therapy unless your clinician changes it, and make sure you have a safe plan for treating a flare.
This article is for informational purposes only and does not replace medical advice. Always talk to your healthcare provider about gout management and medication changes.
